Friday, September 30, 2022


Biotechnology News Magazine

Phase IIb Clincial Trial of Monepantel in Pet Dogs with Treatment Naive B Cell Lymphoma

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

March 30 2021

PharmAust Limited provided an update on its Phase IIb trial evaluating the effects of monepantel upon pet owners’ dogs with treatment-naïve B cell lymphoma.

To date, six dogs with stage 4 to 5 B-cell lymphoma have completed assessments across the five participating trial sites. Treatment of one dog was not in compliance with the dosing instructions (MPL after meal) and that dog was withdrawn from the trial.

Some mild and occasional inappetence was reported in some dogs but this appears insignificant and difficult to attribute solely to MPL. Pleasingly, side-effect levels to date are below those of other conventional anticancer drugs and trial veterinarians report that, at day 28, all participating dogs have been in good spirits and well within themselves. As such the owners have elected to continue treating their dogs with MPL on compassionate use, post-trial.

A further six pet dogs that did not meet the trial inclusion criteria are also being treated under compassionate use with MPL in varying combinations with other anticancer drugs.

Importantly, PharmAust will perform an interim analysis of MPL and MPLS blood levels being achieved in this trial. Determination of these levels will provide a conservative baseline threshold for the very satisfactory side-effect profile observed. The levels will also provide invaluable information for establishing future stand-alone and/or combination treatment regimens for Phase III trials in dogs.

Furthermore, the pharmacokinetic data extracted will provide important information for forthcoming trials in humans.

PharmAust’s Chief Scientific Officer Dr Richard Mollard commented, “It is very satisfying to see minimal side effects after the observed inappetence during the first trial with the tablets. This gives PharmAust plenty of room to further monepantel testing as a standalone therapy or in combination with other drugs in future larger trials.”

University of Melbourne Senior Lecturer (Oncology) Dr Claire Cannon, the principal investigator overseeing the trial, stated, “Monepantel is being well tolerated by the dogs in this study to date with most dogs having no adverse events reported and those that were reported being mild.”

The Phase IIb trial is still recruiting and progressing. The principal investigator is evaluating results and trial data release will occur when clear and meaningful outcomes become apparent.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine